JSP191-Based Conditioning

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
40 patients (estimated)
Sponsors
National Cancer Institute (NCI)
Tags
Allogeneic Stem Cell Transplant, Monoclonal Antibody
Trial Type
Treatment
Last Update
3 weeks ago
SparkCures ID
1734
NCT Identifier
NCT05907746

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.